BioForum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BioForum

Weighing Access and Affordability

November 2, 2012

Pharmaceutical Technology

Policymakers must balance fundamental issues involving access to medicines and pricing.

Shifts in Pharma Capital Agendas

October 2, 2012

Pharmaceutical Technology

The long-awaited patent cliff that has loomed in the pharmaceutical industry for years has arrived in earnest in 2012, with more than $40 billion in 2011 brand sales facing loss of exclusivity.

Small Changes, System-Wide Impact

August 2, 2012

Pharmaceutical Technology

A look at elastomer changeout times shows how industry knowledge improves operations and cost.

A New R&D Paradigm

July 2, 2012

Pharmaceutical Technology

Holistic open learning networks offer a new drug R&D model for improving research outcomes.

Innovation Boom Towns

June 2, 2012

Pharmaceutical Technology

Partnerships between industry and academic medical centers are expanding to meet R&D needs.

A Sustainable Biotech Path

April 2, 2012

Pharmaceutical Technology

With financing constrained, biotechnology firms must find ways to sustain innovation.

Defining Conflict of Interest

March 2, 2012

Pharmaceutical Technology

The divide between innovation and conflict of interest in medical research is not so clear.

Single-Use High Capacity Membrane Chromatography

February 2, 2012

Pharmaceutical Technology

Debottlenecking downstream mAb purification.

Venture-Capital Funding Falls but Shows Some Momentum

January 2, 2012

Pharmaceutical Technology

Challenges remain, particularly for early-stage biopharmaceutical companies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here